Atossa Genetics (ATOS) Competitors $1.18 +0.08 (+6.76%) As of 11:24 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATOS vs. OCGN, INBX, CMPX, FULC, RAPT, CYRX, GLUE, PRTC, SLDB, and ADCTShould you be buying Atossa Genetics stock or one of its competitors? The main competitors of Atossa Genetics include Ocugen (OCGN), Inhibrx Biosciences (INBX), Compass Therapeutics (CMPX), Fulcrum Therapeutics (FULC), Rapt Therapeutics (RAPT), CryoPort (CYRX), Monte Rosa Therapeutics (GLUE), PureTech Health (PRTC), Solid Biosciences (SLDB), and ADC Therapeutics (ADCT). These companies are all part of the "pharmaceutical products" industry. Atossa Genetics vs. Its Competitors Ocugen Inhibrx Biosciences Compass Therapeutics Fulcrum Therapeutics Rapt Therapeutics CryoPort Monte Rosa Therapeutics PureTech Health Solid Biosciences ADC Therapeutics Atossa Genetics (NASDAQ:ATOS) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations. Does the media prefer ATOS or OCGN? In the previous week, Ocugen had 2 more articles in the media than Atossa Genetics. MarketBeat recorded 4 mentions for Ocugen and 2 mentions for Atossa Genetics. Ocugen's average media sentiment score of 0.78 beat Atossa Genetics' score of 0.00 indicating that Ocugen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atossa Genetics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ocugen 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of ATOS or OCGN? 12.7% of Atossa Genetics shares are held by institutional investors. Comparatively, 10.3% of Ocugen shares are held by institutional investors. 7.6% of Atossa Genetics shares are held by company insiders. Comparatively, 4.4% of Ocugen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more risk & volatility, ATOS or OCGN? Atossa Genetics has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, Ocugen has a beta of 4.2, indicating that its share price is 320% more volatile than the S&P 500. Is ATOS or OCGN more profitable? Atossa Genetics has a net margin of 0.00% compared to Ocugen's net margin of -1,197.71%. Atossa Genetics' return on equity of -40.28% beat Ocugen's return on equity.Company Net Margins Return on Equity Return on Assets Atossa GeneticsN/A -40.28% -37.10% Ocugen -1,197.71%-255.25%-86.79% Which has higher valuation & earnings, ATOS or OCGN? Atossa Genetics has higher earnings, but lower revenue than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Atossa Genetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtossa GeneticsN/AN/A-$25.50M-$0.23-5.15Ocugen$4.05M132.44-$54.05M-$0.20-9.18 Do analysts rate ATOS or OCGN? Atossa Genetics presently has a consensus price target of $6.25, suggesting a potential upside of 427.43%. Ocugen has a consensus price target of $6.00, suggesting a potential upside of 226.98%. Given Atossa Genetics' stronger consensus rating and higher probable upside, research analysts plainly believe Atossa Genetics is more favorable than Ocugen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atossa Genetics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75Ocugen 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryAtossa Genetics beats Ocugen on 10 of the 16 factors compared between the two stocks. Get Atossa Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATOS vs. The Competition Export to ExcelMetricAtossa GeneticsMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$153.07M$6.94B$9.08B$10.58BDividend YieldN/A1.16%5.69%4.71%P/E Ratio-5.1527.6486.1627.45Price / SalesN/A195.39539.92202.26Price / CashN/A21.7337.9261.55Price / Book2.085.4113.056.77Net Income-$25.50M$178.04M$3.30B$275.88M7 Day Performance28.80%4.80%4.55%2.63%1 Month Performance46.84%12.80%9.73%9.10%1 Year Performance-15.36%33.92%85.10%35.69% Atossa Genetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATOSAtossa Genetics2.1591 of 5 stars$1.19+6.8%$6.25+427.4%-21.8%$153.07MN/A-5.158News CoverageAnalyst ForecastHigh Trading VolumeOCGNOcugen1.5533 of 5 stars$1.82+2.8%$6.00+229.7%+86.8%$517.38M$4.05M-9.1080Positive NewsAnalyst ForecastINBXInhibrx Biosciences1.0171 of 5 stars$34.96-1.9%N/A+110.2%$516.41M$200K-3.30166News CoverageAnalyst ForecastCMPXCompass Therapeutics2.5968 of 5 stars$3.67-0.8%$13.10+256.9%+125.4%$511.64M$850K-8.1620News CoverageAnalyst ForecastAnalyst RevisionGap UpFULCFulcrum Therapeutics0.8204 of 5 stars$9.50+3.0%$9.60+1.1%+172.0%$498.72M$80M-7.79100News CoveragePositive NewsAnalyst ForecastRAPTRapt Therapeutics3.4906 of 5 stars$29.87-0.9%$23.50-21.3%+95.7%$498.45M$1.53M-2.1180Analyst ForecastCYRXCryoPort3.4212 of 5 stars$9.98+3.1%$12.56+25.8%+44.6%$484.65M$228.38M7.501,186Positive NewsAnalyst ForecastGLUEMonte Rosa Therapeutics2.1764 of 5 stars$7.66-1.0%$15.33+100.2%+54.2%$478.02M$75.62M21.2890Positive NewsAnalyst ForecastPRTCPureTech Health0.0773 of 5 stars$18.76-1.7%N/A-6.6%$461.13M$4.83M0.00100News CoverageAnalyst ForecastGap DownSLDBSolid Biosciences2.7649 of 5 stars$5.48-7.1%$15.00+173.7%-10.9%$459.43M$8.09M-1.96100News CoverageAnalyst ForecastADCTADC Therapeutics2.87 of 5 stars$4.43+8.6%$7.75+74.9%+47.9%$459M$70.84M-2.82310Analyst ForecastAnalyst RevisionGap UpHigh Trading Volume Related Companies and Tools Related Companies OCGN Alternatives INBX Alternatives CMPX Alternatives FULC Alternatives RAPT Alternatives CYRX Alternatives GLUE Alternatives PRTC Alternatives SLDB Alternatives ADCT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATOS) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA Huge Shift Is Underway in AmericaWall Street legend issues chilling new warning: "I've never seen anything as dangerous as this" The man who...Stansberry Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atossa Genetics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atossa Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
